The Cordis SELUTION SLR SUSTANE™ PTA Drug Eluting Balloon achieves highest reported Primary Patency in US IDE Trial

Cordis said its SELUTION SLR SUSTANE PTA drug-eluting balloon achieved 90.3% 12-month primary patency in the SELUTION4SFA US pivotal trial, described as the highest reported result. The findings were presented by Jay Mathews, MD, MS, during a Late-Breaking Clinical Trial session at VIVA 2026; the provided article text includes no further trial details.

Analysis

The result may improve Cordis’s position in peripheral intervention, but a “highest reported” 12-month patency figure is not evidence of superiority absent comparable populations, endpoint definitions, adjudication, and head-to-head statistics. Patency is also only one part of adoption: clinicians and hospital buyers will weigh safety, reintervention, deliverability, reimbursement, and durability beyond one year. The press-release framing therefore supports a commercial watch, not a read-through to durable share gains.

Over the next 1–3 months, the key catalysts are the full trial presentation and any FDA filing or regulatory update; verify sample size, comparator, confidence intervals, safety, and freedom from target-lesion revascularization. Over 6–18 months, the consequential signal would be approval followed by evidence of physician uptake and repeat utilization. If validated, stronger differentiation could pressure competing peripheral drug-coated-balloon platforms, including those of Medtronic, Boston Scientific, and Philips, through hospital contracting and physician preference—not necessarily through an immediate market-wide volume increase.

The contrarian risk is that investors or commercial teams overread a ranking across studies: trial mix and follow-up can make cross-trial comparisons misleading, while adoption can lag clinical data. No company identities or ticker mapping are supplied, so there is no grounded direct equity expression here.

Key Decisions for Investors

• No immediate trade: treat the announcement as a product- and regulatory-watch item, not a basis to short competing device companies or infer a Cordis valuation impact.
• Set an alert for the full SELUTION4SFA dataset and FDA updates. Upgrade the commercial thesis only if endpoint definitions and comparator data support the headline result and safety is acceptable.
• Track 1–3 month evidence on regulatory timing and, over 6–18 months, utilization, repeat orders, and reimbursement. These are the conversion points from trial performance to revenue or competitive pressure.
• Falsification signals: weaker full-data results than the release implies, safety concerns, delayed or unfavorable regulatory action, or no evidence of adoption after commercialization.